趋化因子受体
CX3CL1型
CXCL1型
趋化因子
趋化因子受体
医学
受体
CX3CR1型
免疫学
内科学
作者
Ya‐Qun Zhou,Hengyi Gao,Xue-Hai Guan,Xun Yuan,Guangguang Fang,Yuan Chen,Dawei Ye
标识
DOI:10.2174/1381612821666150831141931
摘要
Bone cancer pain (BCP) is still an intractable problem currently because the analgesic pharmacological intervention remains insufficient. Thus, the development of novel therapeutic target is critical for the treatment of BCP. Emerging evidence demonstrated that some chemokines and their receptors contribute to the induction and maintenance of BCP. In this article, we reviewed the current evidence for the role of different chemokines and their receptors (e.g. CXCL12/CXCR4, CXCL1/CXCR2, CCL2/CCR2, CCL5/CCR5, CX3CL1/CX3CR1 and CXCL10/CXCR3) in mediating BCP. By extensively understanding the involvement of chemokines and their receptors in BCP, novel therapeutic targets may be revealed for the treatment of BCP. Keywords: Bone cancer pain, chemokine, chemokine receptor, therapeutic target.
科研通智能强力驱动
Strongly Powered by AbleSci AI